| Diseases
> Cancer and Tumorous Disease
> Prostate Cancer
Prostate cancer is one of the most common illnesses in older
men. It is detected by routine examination of the prostate
in 20% of 60 year-old men, and in 60% of 80 year-old men,
even when the patient has no symptoms. The minor symptoms
of prostate cancer can be deceptive; it is a very serious
disease. A small, early-phase carcinoma lying in the urethra
can get into the bloodstream via the sperm or urine. Lying
within the prostate, these small carcinomas cause no discomfort,
and generally cannot be found this early except through a
PSA test. It is entirely possible for the cancer tissue to
go undetected for a long time. The typical prostate complaints
of slight or reduced urination, occasional burning during
urination or difficult urination, or post-urination drip are
some non-specific symptoms that can appear in normal cases
as well as in older men experiencing prostate enlargement.
One of the best options for detecting prostate cancer is palpation
of the prostate by a physician to discover a lump or hardening
in the normally elastic prostate tissue. Another very informative
early detection test, which can also be a part of treatment,
is the test for PSA (Prostate Specific Antigen) in the blood.
PSA is a substance that the prostate cancer cells give off,
and which can be measured in the blood. In the normal prostate
enlargement that is associated with age and hormonal change,
test readings are negative or slightly raised. With a new
test, the PSA can be divided into total and “free”
PSA. According to the proportion of “free” PSA
relative to the total PSA, normal or abnormal prostate enlargement
can be indicated. Another even newer test that is used in
PBM for early detection of tumor growth is the TPS (Tissue
Polypeptide Specific Antigen) test, which indicates early
metastasis and tumor growth.
As metastasis appears in the cells, it frequently spreads
to the bones and lymphatic system. Its presence in the bone
can be detected by measuring alkaline phosphatase in the blood.
The more active the bone displacement by cancer cells, the
higher the alkaline phosphatase. Somewhat more specific is
the Acid Prostate-Phosphatase test. Two other somewhat more
costly tests for metastasis are x-ray and skeletocintigraphy.
In this later test, a small amount of radioactive material
is injected and accumulates in the prostate-metastasized tissue
in the bone, and is detected via fluororadiography. Other
early indicator tests are the Thermoregulation Diagnostic,
Darkfield microscopy of the blood, and BioTerrain Assessment.
These give indications as to how the carcinoma tendency should
be treated and which biological therapies should be assembled.
From the PBM perspective, development of tumors is reflective
of a tendency toward degenerative disease. This tendency toward
cancer is often precipitated by the presence of heavy metals
in the body, poisons from root canals, trace element and vitamin
deficiencies, and severe emotional stress, among other factors.
The therapeutic must address this underlying tendency toward
cancer as well as the tumorous condition itself. Treatment
includes vitamin therapy, enzyme therapy, strengthening the
immune system, blood cleansing with isopathic therapies, and
especially dental assessment with heavy m
etal removals.
In certain prostate carcinomas, dose hormone therapy may be
injected in and around the tumor; this has been known to bring
down the PSA value within a month. This individual hormone
dosage is combined with antibody-binding Haptenen (a specific
polysaccharide molecule and cytokines (substances that stimulate
tumor-killing lymphocytes). This treatment in combination
with local hyperthermia is particularly effective in dropping
PSA; the drop indicates a reduction in tumor size and infiltration.
The overall prostate treatment takes at least a year to reach
full effectiveness, but the results are outstanding: 80% of
our cases achieve a halt or a retreat in tumor growth. We
do not recommend chemotherapy for prostate carcinoma, as the
success rate is very low, We seldom recommend surgery early
on for the same reason: in most cases, it offers no more success
than other treatments.
Three further important components of the Paracelsus Tumor
Healthcare Program are:
| • |
Local Hyperthermia (Indiba): A heat therapy
using current technology with deep heating of the local
tissue area. A very high local heat is produced, particularly
in firm tissue. Tumor cells do not support this level
of heat, and die back while healthy tissue is strengthened
in the heat. Metabolism is also increased by this treatment.
Hyperthermia is applied locally and is totally painless.
Application is ideally two to three times per week; for
some individuals, this treatment works well with fewer
applications. This therapy is a specialty of the Paracelsus
Clinic and is practiced nowhere else in Switzerland. Within
about twenty treatments, the tumor tissue can be regenerated
bringing about a scarring over and connective tissue change
in the tumor. |
| •
| Mistletoe Therapy: Mistletoe therapy, which is an injection
of a mistletoe preparation, is a well-researched tumor
treatment, and a pillar of the Paracelsus tumor treatment.
In prostate cancer, the pre
parations are injected subcutaneously
in the groin or abdomen by the patient in increasing dosages
twice weekly. The patient is taught the simple injection
technique. |
• |
In addition to these specifically named cancer treatments,
we follow an ongoing protocol of rebuilding the inner
environment, and treatment and removal of all factors
that lead to the malignant degeneration of the tissue. |
We call these therapies the Paracelsus Tumor
Healthcare Program. Further information on the Tumor Healthcare
Program can be found here.
|
